Article: article from journal or magazin.
Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo.
Neurobiology of Disease
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Huntington's disease (HD) results from an abnormal polyglutamine extension in the N-terminal region of the huntingtin protein. This mutation causes preferential degeneration of striatal projection neurons. We previously demonstrated, in vitro, that dopaminergic D2 receptor stimulation acted synergistically with mutated huntingtin (expHtt) to increase aggregate formation and striatal death. In the present work, we extend these observations to an in vivo system based on lentiviral-mediated expression of expHtt in the rat striatum. The early and chronic treatment with the D2 antagonist haloperidol decanoate protects striatal neurons from expHtt-induced dysfunction, as analyzed by DARPP-32 and NeuN stainings. Haloperidol treatment also reduces aggregates formation, an effect that is maintained over time. These findings indicate that D2 receptors activation contributes to the deleterious effects of expHtt on striatal function and may represent an interesting early target to alter the subsequent course of neuropathology in HD.
Age Factors, Animals, Antipsychotic Agents/therapeutic use, Cell Count/methods, Corpus Striatum/metabolism, Corpus Striatum/pathology, Disease Models, Animal, Dopamine and cAMP-Regulated Phosphoprotein 32/metabolism, Female, Gene Expression Regulation/drug effects, Haloperidol/analogs & derivatives, Haloperidol/therapeutic use, Huntington Disease/genetics, Huntington Disease/pathology, Lentivirus/physiology, Mutation/physiology, Nerve Tissue Proteins/genetics, Neurons/drug effects, Nuclear Proteins/genetics, Phosphopyruvate Hydratase/metabolism, Rats, Rats, Wistar
Web of science
Last modification date